Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries

Vaccine

Volumn 26, Issue SUPPL. 10, 2008, Pages

  Cuzick, Jack ^a   Arbyn, Marc ^b   Sankaranarayanan, Rengaswamy ^c   Tsu, Vivien ^d   Ronco, Guglielmo ^e   Mayrand, Marie Helene ^f   Dillner, Joakim ^g   Meijer, Chris J L M ^h  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d PATH   (United States)

^e Centre for Cancer Prevention   (Italy)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g LUND UNIVERSITY   (Sweden)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Algorithms; Cervical screening; Cytology; HPV testing; Meta analysis; Post treatment surveillance; Psychosocial aspects; Triage; Visual inspection

Indexed keywords

ACETIC ACID; LUGOL; VIRUS DNA; VIRUS MESSENGER RNA; VIRUS PROTEIN;

ALGORITHM; ANXIETY; ARTICLE; CANCER SCREENING; COLPOSCOPY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE FREE INTERVAL; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INTERMETHOD COMPARISON; NONHUMAN; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SCREENING TEST; SELF EXAMINATION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS INFECTION; VISION; WART VIRUS; WOMEN'S HEALTH;

CERVIX UTERI; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 50849143179     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.019     Document Type: Article

References (51)

1. Parkin D.M. Screening for cervix cancer in developing countries. In: Miller A.B., Chamberlain J., Day N.E., Hakama M., and Proroc P.C. (Eds). Cancer screening (1991), Cambridge University Press, Cambridge 184-198
2. Sasieni P., and Adams J. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. BMJ 318 7193 (1999) 1244-1245
3. van der Aa M.A., Pukkala E., Coebergh J.W., Anttila A., and Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer 122 8 (2008) 1854-1858
4. Bulkmans N.W., Rozendaal L., Voorhorst F.J., Snijders P.J., and Meijer C.J. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer 92 9 (2005) 1800-1802
5. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. Br Med J (Clin Res Ed) 1986; 293(6548):659-64.
6. Sasieni P.D., Cuzick J., and Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 73 8 (1996) 1001-1005
7. Sepulveda C., and Prado R. Effective cervical cytology screening programmes in middle-income countries: the Chilean experience. Cancer Detect Prev 29 5 (2005) 405-411
8. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D., Gordillo-Tobar A., Levin C., Mahe C., et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 353 20 (2005) 2158-2168
9. Arbyn M., Bergeron C., Klinkhamer P., Martin-Hirsch P., Siebers A.G., and Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 111 1 (2008) 167-177
10. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., and Dillner J. Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 24 Suppl 3 (2006) S78-S89
11. Arbyn M., Buntinx F., Van Ranst M., Paraskevaidis E., Martin-Hirsch P., and Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 96 4 (2004) 280-293
12. Arbyn M., Paraskevaidis E., Martin-Hirsch P., Prendiville W., and Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 99 3 Suppl 1 (2005) S7-S11
13. Ronco G., Cuzick J., Segnan N., Brezzi S., Carozzi F., Folicaldi S., et al. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer 43 3 (2007) 476-480
14. Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362 9399 (2003) 1871-1876
15. Moss S., Gray A., Legood R., Vessey M., Patnick J., and Kitchener H. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ 332 7533 (2006) 83-85
16. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 9590 (2007) 890-907
17. Gravitt P., Coutlée F., Iftner T., Sellors J., Quint W., et al. New Technologies in Cervical Cancer Screening. Vaccine 26 Suppl. 10 (2008) K42-K52
18. Jacobs M.V., Snijders P.J., Voorhorst F.J., Dillner J., Forslund O., Johansson B., et al. Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol 52 7 (1999) 498-503
19. Sherman M.E., Lorincz A.T., Scott D.R., Wacholder S., Castle P.E., Glass A.G., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95 1 (2003) 46-52
20. Kjaer S.K., van den Brule A.J., Paull G., Svare E.I., Sherman M.E., Thomsen B.L., et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325 7364 (2002) 572
21. Clavel C., Cucherousset J., Lorenzato M., Caudroy S., Nou J.M., Nazeyrollas P., et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. Br J Cancer 90 9 (2004) 1803-1808
22. Schlecht N.F., Platt R.W., Duarte-Franco E., Costa M.C., Sobrinho J.P., Prado J.C., et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95 17 (2003) 1336-1343
23. Cuzick J., Szarewski A., Mesher D., Cadman L., Austin J., Perryman K., et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study. Int J Cancer 122 10 (2008) 2294-2300
24. Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370 9601 (2007) 1764-1772
25. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357 16 (2007) 1589-1597
26. Ogilvie G.S., Patrick D.M., Schulzer M., Sellors J.W., Petric M., Chambers K., et al. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect 81 3 (2005) 207-212
27. Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Jaspars L.H., Voorhorst F.J., et al. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol 55 6 (2002) 435-439
28. Brink A.A., Meijer C.J., Wiegerinck M.A., Nieboer T.E., Kruitwagen R.F., van Kemenade F., et al. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 44 7 (2006) 2518-2523
29. Szarewski A., Cadman L., Mallett S., Austin J., Londesborough P., Waller J., et al. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. J Med Screen 14 1 (2007) 34-42
30. Bais A.G., van Kemenade F.J., Berkhof J., Verheijen R.H., Snijders P.J., Voorhorst F., et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 120 7 (2007) 1505-1510
31. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 9576 (2007) 1861-1868
32. Gaffikin L., Blumenthal P.D., Emerson M., and Limpaphayom K. Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project. Lancet 361 9360 (2003) 814-820
33. Blumenthal P.D., Lauterbach M., Sellors J.W., and Sankaranarayanan R. Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy. Int J Gynaecol Obstet 89 Suppl. 2 (2005) S30-S37
34. Sankaranarayanan R., Gaffikin L., Jacob M., Sellors J., and Robles S. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 89 Suppl. 2 (2005) S4-S12
35. Jeronimo J., and Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol 195 2 (2006) 349-353
36. Arbyn M., Sankaranarayanan R., Muwonge R., Keita N., Dolo A., Mbalawa C.G., et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 123 1 (2008) 153-160
37. Denny L., Kuhn L., Pollack A., and Wright Jr. T.C. Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer 94 6 (2002 Mar 15) 1699-1707
38. Sankaranarayanan R., Nene B.M., Dinshaw K.A., Mahe C., Jayant K., Shastri S.S., et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 116 4 (2005) 617-623
39. Sankaranarayanan R., Esmy P.O., Rajkumar R., Muwonge R., Swaminathan R., Shanthakumari S., et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 370 9585 (2007) 398-406
40. Sankaranarayanan R., Basu P., Wesley R.S., Mahe C., Keita N., Mbalawa C.C., et al. Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer 110 6 (2004) 907-913
41. Sarian L.O., Derchain S.F., Naud P., Roteli-Martins C., Longatto-Filho A., Tatti S., et al. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study. J Med Screen 12 3 (2005) 142-149
42. Alliance for Cervical Cancer Prevention (ACCP). Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers (2004), ACCP, Seattle
43. Denny L., Kuhn L., De Souza M., Pollack A.E., Dupree W., and Wright Jr. T.C. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 294 17 (2005) 2173-2181
44. Wardle J., Waller J., Brunswick N., and Jarvis M.J. Awareness of risk factors for cancer among British adults. Public Health 115 3 (2001) 173-174
45. Waller J., McCaffery K., Forrest S., Szarewski A., Cadman L., and Wardle J. Awareness of human papillomavirus among women attending a well woman clinic. Sex Transm Infect 79 4 (2003) 320-322
46. Dell D.L., Chen H., Ahmad F., and Stewart D.E. Knowledge about human papillomavirus among adolescents. Obstet Gynecol 96 5 Pt 1 (2000) 653-656
47. Anhang R., Goodman A., and Goldie S.J. HPV communication: review of existing research and recommendations for patient education. CA Cancer J Clin 54 5 (2004) 248-259
48. Bulkmans N.W., Bulk S., Ottevanger M.S., Rozendaal L., Hellenberg S.M., van Kemenade F.J., et al. Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate. J Clin Pathol 59 11 (2006) 1218-1220
49. Anhang R., Wright Jr. T.C., Smock L., and Goldie S.J. Women's desired information about human papillomavirus. Cancer 100 2 (2004) 315-320
50. McCaffery K., Waller J., Nazroo J., and Wardle J. Social and psychological impact of HPV testing in cervical screening: a qualitative study. Sex Transm Infect 82 2 (2006) 169-174
51. McCaffery K., Forrest S., Waller J., Desai M., Szarewski A., and Wardle J. Attitudes towards HPV testing: a qualitative study of beliefs among Indian, Pakistani, African-Caribbean and white British women in the UK. Br J Cancer 88 1 (2003) 42-46